October 2010

Because specialty drug expenditures will grow, P&T committees may become more involved with drugs provided under the medical benefit
CFS is one of a number of diseases with an uncertain etiology and a substantial effect on patients but with few or no verified treatments
A consultant urges plans to streamline Web sites and devise new contracting strategies to prepare for an influx of individual customers
Its new branding campaign may be a ‘right mistake’
A new system set to start in 2012 will tie allocations to how well insurers hit quality benchmarks. There’s a curve, too.
A straightforward method of identifying potentially non-urgent ED visits from administrative data can be employed to calculate population-based rates, which might be applied in the development of managed care programs


Legislation & Regulation
Federal auditors tell CMS it has been deficient in monitoring whether states are treating plans fairly
Tomorrow’s Medicine
For cosmetic reasons, this type of hearing system is desirable, but how much does it cost and who are the best candidates?